Across TCGA pan-cancer cohorts, SRPRA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRPRA data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SRPRA mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SRPRA expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where SRPRA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	27	view →
LUAD	OS	Median	II,III,IV	0.800	0.486	.012	15	view →
GBM	OS	Quartile	All	0.342	0.637	.007	9	view →
PDAC	DFS	Tertile	IV	0.205	0.741	.024	3	view →
LSCC	OS	Tertile	All	1.000	0.949	.038	3	view →
HNSC	DFS	Median	IV	0.889	0.407	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SRPRA tumor-vs-normal RNA expression · all SRPRA data types